Analytical Data
-
基因名
CYP3A4
- Application
-
别名
CYP3A4；CYP3A3；Cytochrome P450 3A4
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P08684
-
表达区间
2-503aa
-
氨基酸序列
ALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGA-
-
分子量
63.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP3A4 is a member of the cytochrome P450 enzyme family and plays a critical role in the metabolism of a wide variety of drugs and endogenous compounds in the human liver and intestines. As the most abundant P450 enzyme in the human body, CYP3A4 is responsible for the biotransformation of approximately 50% of all pharmaceuticals, including several anticancer medications, antihypertensives, and antiepileptic drugs. Its activity can be significantly influenced by various factors, including genetic polymorphisms, dietary components, and drug-drug interactions, leading to variability in drug efficacy and toxicity among individuals. The recombinant expression of CYP3A4 in heterologous systems, such as bacteria and yeast, has become a vital research tool, allowing scientists to study its enzymatic properties, substrate specificity, and potential inhibitors. The generation of recombinant CYP3A4 enables the exploration of drug metabolism pathways and provides insights into the mechanisms of drug interactions, making it an essential component in drug development and personalized medicine. Understanding the structure-function relationship and regulatory mechanisms of CYP3A4 can pave the way for better therapeutic strategies and safer drug administration, ultimately improving patient outcomes in clinical settings.
